Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Organoid Drug Sensitivity Testing-Guided Adjuvant Therapy in HCC
NCT07363356Phase 2Not yet recruiting
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Jan 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 2, open-label trial in hepatocellular carcinoma (HCC) (2 arms), sponsored by Eastern Hepatobiliary Surgery Hospital. Primary endpoints: Recurrence-Free Survival at 5 years, 1-year Recurrence-Free Survival rate and 2 more. Planned start Jan 2026; status: not yet recruiting.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07363356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07363356.